Condition (MeSH)
Hyperandrogenism
ClinicalTrials.gov lists 80 trials for Hyperandrogenism or a narrower condition beneath it. National Institute of Environmental Health Sciences (NIEHS) has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
80 of the 80 trials are tagged with Hyperandrogenism itself; the rest are tagged with a narrower condition beneath it.
When did Hyperandrogenism trials start? (26)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 8 |
| 2025 | 2 |
| 2024 | 1 |
| 2023 | 3 |
| 2022 | 1 |
| 2021 | 5 |
| 2020 | 3 |
| 2019 | 5 |
| 2018 | 4 |
| 2017 | 2 |
Showing 10 of 26 earlier years.
No forecast is made for this condition: it averages 3.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Hyperandrogenism trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 6 |
| Phase 1/2 | 1 |
| Phase 2 | 9 |
| Phase 3 | 2 |
| Phase 4 | 9 |
| Not applicable | 25 |
| Observational | 28 |
How many Hyperandrogenism trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 4 |
| Recruiting | 11 |
| Enrolling by invitation | 2 |
| Completed | 36 |
| Suspended | 1 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Hyperandrogenism trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute of Environmental Health Sciences (NIEHS) | 2 |
| 59th Medical Wing | 1 |
| Clinique Ovo | 1 |
Which drugs are being tested for Hyperandrogenism? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| .spironolactone | 3 |
| Estradiol | 2 |
| Salsalate | 2 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| 1% Metformin | 10 |
| Progesterone 8% | 3 |
| clomiphen citrate | 2 |
| Micronized Progesterone | 2 |
| Flutamide 1% gel | 2 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Hyperandrogenism trials report? (2)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome | 1 | 1 |
| Undisclosed Exclusion Criteria - Symptoms and History of Migraines with Aura | 1 | 1 |
Which publications cover Hyperandrogenism? (163)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Polycystic ovary syndrome. | Nature reviews. Disease primers | 2024 | Yes |
| Sexual dimorphism in anxiety is programmed in-utero by sex-steroids: Proof of concept using a disease-model and stress responses to COVID pandemic. | Psychiatry research | 2024 | Yes |
| Hypothalamic-Ovarian axis and Adiposity Relationship in Polycystic Ovary Syndrome: Physiopathology and Therapeutic Options for the Management of Metabolic and Inflammatory Aspects. | Current obesity reports | 2024 | Yes |
| Maternal serum levels of prokineticin-1 related to pregnancy complications and metformin use in women with polycystic ovary syndrome: a post hoc analysis of two prospective, randomised, placebo-controlled trials. | BMJ open | 2023 | Yes |
| Role of C-type natriuretic peptide in polycystic ovary syndrome. | International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics | 2023 | Yes |
Showing 5 of 163 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.